Toshikazu D Tanaka Selected Research

Toshikazu D Tanaka Research Topics

Disease

4	Insulin Resistance 01/2022 - 01/2017
3	Heart Failure 01/2022 - 07/2013
3	Pulmonary Hypertension 07/2021 - 06/2018
3	Ischemia 03/2021 - 01/2015
3	Left Ventricular Dysfunction 01/2021 - 01/2017
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 03/2020
3	Acute Coronary Syndrome 03/2019 - 01/2017
2	Obesity 01/2022 - 01/2019
2	Pulmonary Arterial Hypertension 07/2021 - 06/2018
2	Myocardial Infarction 03/2019 - 07/2013
2	Infarction (Infarctions) 01/2019 - 01/2015
2	Reperfusion Injury 01/2019 - 01/2015
2	Myocardial Ischemia (Ischemic Heart Diseases) 01/2017 - 01/2017
1	Necrosis 01/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022
1	Hyperuricemia 01/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Dyspnea (Shortness of Breath) 07/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 07/2021
1	Vascular Diseases (Vascular Disease) 07/2021
1	Cardiotoxicity 01/2021
1	Arteriosclerosis 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Sarcoidosis (Schaumann Disease) 12/2020
1	Pulmonary Sarcoidosis 12/2020
1	Hyperglycemia 03/2020
1	Dyslipidemias (Dyslipidemia) 03/2020
1	Autoimmune Pancreatitis 03/2019
1	Immunoglobulin G4-Related Disease 03/2019
1	POEMS Syndrome (Syndrome, POEMS) 06/2018
1	Ischemic Contracture 01/2015

Drug/Important Bio-Agent (IBA)

4	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 01/2015
3	Insulin (Novolin)FDA Link 01/2022 - 01/2017
3	Uric Acid (Urate)IBA 01/2022 - 01/2017
3	LipidsIBA 01/2022 - 03/2020
2	Vasodilator Agents (Vasodilators)IBA 07/2021 - 01/2021
2	Adenosine Triphosphate (ATP)IBA 01/2021 - 01/2015
2	Natriuretic PeptidesIBA 01/2021 - 01/2019
2	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2021 - 01/2021
2	Malondialdehyde (Propanedial)IBA 01/2021 - 03/2020
2	LDL Lipoproteins (beta Lipoproteins)IBA 01/2021 - 03/2020
2	oxidized low density lipoproteinIBA 01/2021 - 03/2020
2	PhlorhizinIBA 01/2019 - 01/2015
1	dotinuradIBA 01/2022
1	IvabradineIBA 01/2022
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2022
1	LigandsIBA 01/2022
1	MineralsIBA 01/2022
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2022
1	Steroid Receptors (Steroid Receptor)IBA 01/2022
1	Neprilysin (Neutral Endopeptidase)IBA 01/2022
1	CytokinesIBA 01/2022
1	ChemokinesIBA 01/2022
1	Sodium-Glucose Transport ProteinsIBA 01/2022
1	Phosphodiesterase 5 InhibitorsIBA 07/2021
1	Tadalafil (Cialis)FDA Link 07/2021
1	NitratesIBA 03/2021
1	Therapeutic UsesIBA 01/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021
1	Xanthine OxidaseIBA 01/2021
1	Atrial Natriuretic Factor (ANF)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	low density lipoprotein inhibitorIBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	purineIBA 01/2021
1	GadoliniumIBA 12/2020
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 12/2020
1	Blood Glucose (Blood Sugar)IBA 03/2019
1	Immunoglobulin G (IgG)IBA 03/2019
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2019
1	N-formyl-13-dihydrocarminomycin (NFD)IBA 01/2019
1	Endothelin Receptor AntagonistsIBA 06/2018
1	Thalidomide (Thalomid)FDA Link 06/2018
1	Epoprostenol (Prostacyclin)FDA LinkGeneric 06/2018
1	Dexamethasone (Maxidex)FDA LinkGeneric 06/2018
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 06/2018
1	PotassiumIBA 01/2017
1	triphenyltetrazoliumIBA 01/2015
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2015
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2015
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2013
1	ClenbuterolIBA 07/2013

Therapy/Procedure

5	Therapeutics 01/2022 - 07/2013
1	Percutaneous Coronary Intervention 03/2019
1	Aftercare (After-Treatment) 01/2017